Skip to main content

A Multicenter Interventional Trial Using Blood Mucorales Polymerase Chain Reaction as a Screening Tool in High-Risk Hematology Patients (MUCOPS)

Journal
Open forum infectious diseases (Q1)
Published
28 October 2026
Study design
Unclassified
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Yuri Vanbiervliet, Robina Aerts, Ellen Boon, Kurt Beuselinck, Marijke Reynders, Toine Mercier, et al.
PMID
43061072
DOI
10.1093/ofid/ofag696

Why clinicians should know about it

  • Picked for Microbiology (medical) (top studies of the week, 22 November 2026): Prospective plasma Mucorales PCR screening and diagnostic performance evaluation

Abstract

BACKGROUND: Mucormycosis (MCM) is a life-threatening invasive mold infection. Conventional diagnostics are insensitive. Mucorales polymerase chain reaction (PCR) shows promising diagnostic accuracy, and early blood PCR detection may improve survival. Prospective screening data remain limited. METHODS: MUCOPS was a prospective multicenter interventional study in Belgium. Adults receiving remission-induction chemotherapy for acute myeloid leukemia or myelodysplastic syndrome, or first allogeneic hematopoietic cell transplantation, underwent twice-weekly plasma Mucorales PCR screening (MucorGenius®) for 3 months from treatment initiation. Primary endpoints were the incidence of a positive screening PCR and diagnostic performance. Results were reported within 24-48 hours and integrated into routine care, with performance evaluated against clinical, radiological, and microbiological data. RESULTS: Two hundred patients underwent 2400 plasma PCR tests (median 9 per patient, IQR 6-17); 12 (6.0%) had a positive screening PCR. Five otherwise occult MCM cases (2.5%) were identified: 3 by plasma PCR and 2 by bronchoalveolar lavage fluid (BALF) PCR only. Plasma PCR sensitivity was 83.3%, specificity 99.6%, positive predictive value 52.6%, and negative predictive value (NPV) 99.9%. Positive results triggered investigations and early liposomal amphotericin B (median 1 day, IQR 0.5-2). Three patients had concomitant invasive aspergillosis. In survivors, PCR clearance occurred within 4-7 days. CONCLUSIONS: Twice-weekly plasma Mucorales PCR screening was feasible in high-risk hematology patients, with good sensitivity and excellent specificity and NPV, effectively ruling out MCM. Isolated BALF positivity highlights uncertain clinical significance. Screening detected otherwise occult MCM, enabled early antifungal therapy, and influenced clinical management. These findings support incorporating plasma Mucorales PCR into future definitions and management strategies. CLINICAL TRIAL REGISTRATION: NCT05925660.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.